Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Sebastian Ochsenreither

Charité - Universitätsmedizin Berlin

Germany

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Immunology

50%

Internal Medicine

30%

Cancer Research

50%

Tumor Immunology

40%

Oncology

40%

Cancer Biology

40%

Neoadjuvant Therapy

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles14

Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis.

Year:

2024

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Year:

2024

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Year:

2024

Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial

Year:

2024

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens

Year:

2023

A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

Year:

2022

Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study

Year:

2022

Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC)

Year:

2022

Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG)

Year:

2022

Precision oncology for resistant acral, mucosal and cutaneous melanomas: A prospective broad high throughput genomics feasibility study

Year:

2022

Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltration

Year:

2022

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors (vol 7, 100447, 2022)

Year:

2022

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

Year:

2022

FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow

Year:

2021

Collaborators3

Anja Williams

Scripps Research Institute

UNITED KINGDOM

Frederick Klauschen

Professor, Chair

Ludwig-Maximilians-Universität München

GERMANY

Ulrich Keller

Prof. Dr.

Charité - Universitätsmedizin Berlin

GERMANY

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI